In addition, based on our previous findings showing that increased AREG levels mediate the Rhbdf2cub phenotype [3], and the findings of the present study, we propose that tylosis therapies should be targeted toward inhibition of AREG specifically in the skin. This evidence concerns the gene AREG and Non-epidermolytic palmoplantar keratoderma.